Skip to content
MarketScale
‹ Back to IndustriesSciences

On the way to Space, Billionaires Look for Business Partners

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk. This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · BezosBlue OriginElon MuskScience
Share
On the way to Space, Billionaires Look for Business Partners

Key takeaways

01

The world is in a new space race.

02

This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

03

This billionaire space race, as it is being called, has resulted in the creation of just as many companies.

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s Virgin Galactic may grab the headlines, but there is also Bezos’ Blue Origin, and Milner’s Breakthrough Starshot. The late Paul Allen also started Stratolaunch.

Each is aimed at somewhat different aspects of space travel, but one thing they all have in common is a competitive—and cooperative—spirit that is driving a great deal of technical innovation.

Companies like SpaceX are finding that it is important to partner with other companies to be successful. NASA and companies like Iridium have partnered with SpaceX to put satellites in orbit. Land Rover and Abu Dhabi, meanwhile, have chosen to partner with Virgin Galactic, who is also partnering with Boom Technology to create a supersonic passenger transporter. While SpaceX has NASA, Blue Origin is partnered with the Air Force for launch services.

There is a healthy need for space services and for creating strong partnerships to develop the technology needed, but what new technologies are on the horizon?

SpaceX has been having more and more success with its rockets, and it famously was able to land a rocket on a sea platform. Elon Musk has also been talking about going to Mars, and that will take some serious improvements in technology. In fact, SpaceX is currently working with NASA on developing a Mars-landing mission.

Blue Origin has developed New Shepard, a suborbital, reusable launch vehicle, and New Glenn, an orbital, reusable launch vehicle.

Virgin Galactic has long talked about the creation of a space plane that will make space tourism feasible. On Dec. 13, Virgin Galactic came a lot closer to realizing that dream when it was able to fly its VSS Unity to the edge of space.

With plans for the moon and Mars, including the possibility of 3D printing structures for people to potentially visit or inhabit, the sky is absolutely not the limit for these visionaries. While the space race between the USA and the USSR got man into space in the first place, and even placed a few men on the moon, the billionaires’ space race looks to take space technology, research, and exploration to new heights. Only time will tell what benefits all of this will bring.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

TC
Troy Camplin

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin